Analysis of 36,015 patients across nine studies reveals that renin-angiotensin system (RAS) inhibitors—commonly prescribed blood pressure medications like ACE inhibitors and ARBs—are associated with significantly improved survival after transcatheter aortic valve implantation (TAVI). Patients taking these medications showed 26% lower odds of death, 38% reduced cardiovascular mortality, 41% fewer strokes, and 16% less heart failure hospitalization compared to those not on RAS inhibitors. This finding addresses a critical knowledge gap in post-TAVI care, as severe aortic stenosis affects millions globally and TAVI has become the preferred treatment for many high-risk patients. The cardiovascular protective effects align with established benefits of RAS inhibitors in other heart conditions, suggesting these medications may help the heart adapt to improved blood flow dynamics after valve replacement. However, this preprint meta-analysis relies entirely on observational data, making it impossible to establish causation or rule out confounding factors—healthier patients may be more likely to receive these medications. The lack of randomized controlled trials represents a significant limitation, and results await peer review before clinical practice changes should be considered.